<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00968864</url>
  </required_header>
  <id_info>
    <org_study_id>LCH BMT 09-01</org_study_id>
    <nct_id>NCT00968864</nct_id>
  </id_info>
  <brief_title>T-cell Depleted Alternative Donor Transplantation</brief_title>
  <official_title>A Phase II Study Using the CliniMACS® Device for CD34+ Cell Selection and T Cell Depletion for Graft-versus-Host Disease Prophylaxis in Alternative Donor Stem Cell Transplant Recipients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Andrew Gilman</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Carolinas Healthcare System</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose is to determine the ability of CD34+ selection and T cell depletion using
      the CliniMACS® device to prevent severe acute graft-versus-host disease (GVHD) in patients
      receiving a stem cell transplant from an alternative (unrelated and mismatched related)
      donor. The secondary objectives include evaluation of engraftment, immune recovery, and
      post-transplant infections.

      Patients requiring stem cell transplants for either malignant (cancerous) or non-malignant
      disease will be included in the study. The recipients will be grouped into one of two groups
      based on whether the donor is mismatched related (Cohort A) or unrelated (Cohort B). The
      patient will receive a conditioning regimen including chemotherapy drugs and/or total body
      irradiation based on the disease for which the transplant is performed.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A major issue in alternative donor (mismatched related and unrelated donor transplantation is
      the development of graft-versus-host disease (GVHD). Several clinical trials have shown that
      the use of T-cell depleted peripheral blood stem cells (PBSC) reduces GVHD in alternative
      donor transplants. The purpose of this study is to determine the ability of CD34 positive
      selection and T cell depletion using the CliniMACS® Device as the only GVHD prophylaxis to
      prevent severe acute GVHD in recipients of an alternative donor PBSC transplant. Mismatched
      related donors will match at least 3 of 6 Human leukocyte antigens(HLA)(haplocompatible) and
      unrelated donors will match at least 6 out of 8 HLA antigens with the transplant recipient.
      The conditioning therapy including chemotherapy, anti-thymocyte globulin (ATG), +/- total
      body irradiation (TBI) will be based on the patient's diagnosis. The transplant recipient
      will be followed for 5 years after transplant for GVHD, engraftment, post-transplant
      infections, disease relapse, and overall survival. In addition, this study will serve as a
      platform for a companion study of therapy to accelerate immune recovery after transplant.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Sponsor/ PI leaving institution, no plans to continue this research at this time
  </why_stopped>
  <start_date>August 2009</start_date>
  <completion_date type="Actual">November 2016</completion_date>
  <primary_completion_date type="Actual">November 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Severe Graft vs. Host Disease (GVHD).</measure>
    <time_frame>Within 30 days after stem cell transplant</time_frame>
    <description>Severe GVHD defined as grade III/IV GVHD.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Engraftment and Time to Engraftment</measure>
    <time_frame>Within 28 days after stem cell transplant</time_frame>
    <description>Engraftment was measured as time to absolute neutrophil count &gt;500</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Post-transplant Infections</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With EBV-related Post Transplant Lymphoproliferative Disorder (PTLD)</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Post-transplant Leukemia Relapse</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Transplant-related Mortality</measure>
    <time_frame>2 year</time_frame>
    <description>Transplant-related mortality includes death due to regimen-related toxicity or GVHD (all causes other than disease relapse). Those who died due to disease relapse are not included in the analyzed population for that time point.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Transplant-related Toxicities</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Device Performance: Dose of CD34+ Cells and CD3+ Cells Given</measure>
    <time_frame>Length of the trial (5 years)</time_frame>
    <description>For mismatched related donors, the target cell dose after processing is &gt;/= 20 x 10^6 CD34+ cells/kg patient body weight, but &gt;/= 8 x 10^6 is acceptable.
For unrelated donors the target cell dose after processing is &gt;/= 10 x 10^6 CD34+ cells/kg patient body weight, but &gt;/= 4 x 10^6 is acceptable.
The target T cell dose is &lt;/= 3 x 10^4 CD3+ cells/ kg.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">53</enrollment>
  <condition>Acute Lymphoblastic Leukemia</condition>
  <condition>Acute Myeloid Leukemia</condition>
  <condition>Chronic Myeloid Leukemia</condition>
  <condition>Myelodysplastic Syndrome</condition>
  <condition>Lymphomas</condition>
  <condition>Bone Marrow Failure</condition>
  <condition>Hemoglobinopathy</condition>
  <condition>Immune Deficiency</condition>
  <condition>Osteopetrosis</condition>
  <arm_group>
    <arm_group_label>CliniMACS® (T cell depletion)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Recipients will receive T cell-depleted PBSC from eligible donors after receiving conditioning therapy using CliniMACS® device.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CliniMACS® (T cell depletion)</intervention_name>
    <description>Stem cells will be collected from donors after they receive Granulocyte colony-stimulating factor (G-CSF). The cells will be processed using the CliniMACS device to select for CD34+ stem cells and to deplete T cells. Recipients will receive conditioning therapy that is based on their disease type and then receive the CD34+ stem cells.</description>
    <arm_group_label>CliniMACS® (T cell depletion)</arm_group_label>
    <other_name>CliniMACS device</other_name>
    <other_name>T-cell depletion</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &lt; 30 years

          -  Patient must have a malignant or non-malignant disease that can benefit from
             alternative stem cell transplantation. Examples include acute and chronic leukemias,
             myelodysplastic syndrome, lymphoma, severe acquired and congenital cytopenias, white
             and red blood cell abnormalities, and immunodeficiencies.

          -  Patients with acute lymphoblastic leukemia must be in morphological remission (&lt; 5%
             blasts) at the time of transplant. Patients with acute non-lymphocytic leukemia will
             preferably be in morphologic remission but may be enrolled when aplastic after
             chemotherapy or with &lt; 20% blasts. Patients with lymphoma must be in complete or close
             to complete remission (if residual adenopathy, PET scan must be negative or only have
             slight uptake, eg. SUV &lt; 2).

          -  Patients must lack a healthy HLA-identical related donor of at least one year of age.

          -  Patient must have a mismatched related or an unrelated donor who is:

               1. Able to receive G-CSF and undergo apheresis either through placement of catheters
                  in antecubital veins or a temporary central venous catheter,

               2. Healthy,

               3. Willing,

               4. For recipients of an unrelated donor transplant, recipient eligibility will be
                  restricted as follows if in the judgment of the recipients' transplant physician,
                  the recipient cannot receive a transplant with combined positive and negative
                  fractions as described in Section 6.1.3.2 or an unmanipulated PBSC product.

               5. Meets eligibility criteria for donors.

          -  If only one mismatched related relative is available, an acceptable unrelated donor
             must be identified as a backup.

          -  Patient or authorized guardian must sign informed consent for this study.

        Exclusion Criteria:

          -  Patient with an anticipated life expectancy of &lt; 1 month

          -  Active infectious hepatitis or CMV infection

          -  HIV or HTLV-I/II infection

          -  Serious infection (bacterial, fungal, viral) within the last 4 weeks

          -  Cardiac ejection fraction &lt; 45%; can be lower if patient is not in clinical cardiac
             failure and a reduced intensity conditioning regimen is used.

          -  Creatinine clearance &lt;60 ml/min/1.72 m2; can be lower if a reduced intensity
             conditioning regimen is used.

          -  Pulmonary diffusion capacity (adjusted for Hgb), FEV1, or FVC &lt;60% of predicted or O2
             sat &lt; 94% if unable to perform PFTs; can be lower if a reduced intensity conditioning
             regimen is used.

          -  Serum ALT &gt; 3 x upper limit of normal (can be up to 5 x upper limit of normal if a
             reduced intensity conditioning regimen is used) or bilirubin &gt; 2. The bilirubin
             criteria for sickle cell disease patients is direct bilirubin &gt;2x upper limit of
             normal.

          -  Performance score (Lansky/Karnofsky) &lt; 50

          -  Any condition that compromises compliance with the procedures of this protocol, as
             judged by the principal investigator.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>30 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrew Gilman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Pediatrics, Levine Children's Hospital, Carolinas Healthcare System</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Levine Children's Hospital, Carolinas Medical Center</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 28, 2009</study_first_submitted>
  <study_first_submitted_qc>August 28, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2009</study_first_posted>
  <results_first_submitted>September 9, 2017</results_first_submitted>
  <results_first_submitted_qc>October 8, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">November 8, 2017</results_first_posted>
  <last_update_submitted>October 8, 2017</last_update_submitted>
  <last_update_submitted_qc>October 8, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 8, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Carolinas Healthcare System</investigator_affiliation>
    <investigator_full_name>Andrew Gilman</investigator_full_name>
    <investigator_title>Director, Pediatric Blood and Marrow Transplantation</investigator_title>
  </responsible_party>
  <keyword>T cell depleted</keyword>
  <keyword>Matched unrelated donors</keyword>
  <keyword>Haplocompatible donors</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
    <mesh_term>Immunologic Deficiency Syndromes</mesh_term>
    <mesh_term>Pancytopenia</mesh_term>
    <mesh_term>Hemoglobinopathies</mesh_term>
    <mesh_term>Osteopetrosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Candidates for bone marrow transplant who did not have a healthy HLA-identical related donor, at Levine Children's Hospital between December 2009 and June 2016.</recruitment_details>
      <pre_assignment_details>Subjects were enrolled to two cohorts based on donor type, Mismatched Related Donor (MMRD) and Matched Unrelated Donor (MUD).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>T Cell Depletion Using CliniMACS®</title>
          <description>Recipients will receive T cell-depleted PBSC from eligible donors after receiving conditioning therapy using CliniMACS® device.
CliniMACS® (T cell depletion): Stem cells will be collected from donors after they receive Granulocyte colony-stimulating factor (G-CSF). The cells will be processed using the CliniMACS device to select for CD34+ stem cells and to deplete T cells. Recipients will receive conditioning therapy that is based on their disease type and then receive the CD34+ stem cells.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="53">One patient, FDA and IRB approved to enroll as an exception, was not evaluable for study endpoints.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="52"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol exception/ not evaluable</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>T Cell Depletion Using CliniMACS®</title>
          <description>Recipients will receive T cell-depleted PBSC from eligible donors after receiving conditioning therapy using CliniMACS® device.
CliniMACS® (T cell depletion): Stem cells will be collected from donors after they receive Granulocyte colony-stimulating factor (G-CSF). The cells will be processed using the CliniMACS device to select for CD34+ stem cells and to deplete T cells. Recipients will receive conditioning therapy that is based on their disease type and then receive the CD34+ stem cells.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="52"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Less than 1 year</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1-2 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2-4 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4-6 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6-8 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8-10 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>10-12 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12-14 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>14-16 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>16-18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Greater than 18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Severe Graft vs. Host Disease (GVHD).</title>
        <description>Severe GVHD defined as grade III/IV GVHD.</description>
        <time_frame>Within 30 days after stem cell transplant</time_frame>
        <group_list>
          <group group_id="O1">
            <title>T Cell Depletion Using CliniMACS®</title>
            <description>Recipients will receive T cell-depleted PBSC from eligible donors after receiving conditioning therapy using CliniMACS® device.
CliniMACS® (T cell depletion): Stem cells will be collected from donors after they receive Granulocyte colony-stimulating factor (G-CSF). The cells will be processed using the CliniMACS device to select for CD34+ stem cells and to deplete T cells. Recipients will receive conditioning therapy that is based on their disease type and then receive the CD34+ stem cells.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Severe Graft vs. Host Disease (GVHD).</title>
          <description>Severe GVHD defined as grade III/IV GVHD.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Engraftment and Time to Engraftment</title>
        <description>Engraftment was measured as time to absolute neutrophil count &gt;500</description>
        <time_frame>Within 28 days after stem cell transplant</time_frame>
        <population>There were 2 cases of primary graft failure in the mismatched related donor cohort; both achieved engraftment following a second transplant.</population>
        <group_list>
          <group group_id="O1">
            <title>Mismatched Related Donor Cohort</title>
          </group>
          <group group_id="O2">
            <title>Matched Unrelated Donor Cohort</title>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Engraftment and Time to Engraftment</title>
          <description>Engraftment was measured as time to absolute neutrophil count &gt;500</description>
          <population>There were 2 cases of primary graft failure in the mismatched related donor cohort; both achieved engraftment following a second transplant.</population>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15" lower_limit="9" upper_limit="19"/>
                    <measurement group_id="O2" value="13" lower_limit="10" upper_limit="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Post-transplant Infections</title>
        <time_frame>1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>T Cell Depletion Using CliniMACS®</title>
            <description>Recipients will receive T cell-depleted PBSC from eligible donors after receiving conditioning therapy using CliniMACS® device.
CliniMACS® (T cell depletion): Stem cells will be collected from donors after they receive Granulocyte colony-stimulating factor (G-CSF). The cells will be processed using the CliniMACS device to select for CD34+ stem cells and to deplete T cells. Recipients will receive conditioning therapy that is based on their disease type and then receive the CD34+ stem cells.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Post-transplant Infections</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HHV-6 reactivation, no disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Viral URI (adeno, paraflu, rhino, rsv)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Clostridium difficile colitis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Adenovirus reactivation, no disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bacteremia, gram positive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Candidiasis (not invasive)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sinusitis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bacteremia, gram negative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CMV reactivation, no disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BK virus, no disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EBV-related lymphoproliferative disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BK virus, hemorrhagic cystitis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Adenovirus disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Infection with normal ANC - grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Norovirus</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Positive Galactomannan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Acute otitis media</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HSV - mouth sores</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EBV reactivation, no disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pneumonia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Varicella zoster</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Candidiasis (invasive)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CMV, GI disease/ encephalitis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disseminated aspergillus</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Methicillin-Resistant Staph Aureus</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rotavirus</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nocardia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pneumonia - fungal (non-aspergillus)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Influenza</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Parvovirus B19 (low level)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sapovirus</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Septic arthritis (prosthetic joint)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Possible respiratory infection (rhizomucor)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With EBV-related Post Transplant Lymphoproliferative Disorder (PTLD)</title>
        <time_frame>5 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>T Cell Depletion Using CliniMACS®</title>
            <description>Recipients will receive T cell-depleted PBSC from eligible donors after receiving conditioning therapy using CliniMACS® device.
CliniMACS® (T cell depletion): Stem cells will be collected from donors after they receive Granulocyte colony-stimulating factor (G-CSF). The cells will be processed using the CliniMACS device to select for CD34+ stem cells and to deplete T cells. Recipients will receive conditioning therapy that is based on their disease type and then receive the CD34+ stem cells.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With EBV-related Post Transplant Lymphoproliferative Disorder (PTLD)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Post-transplant Leukemia Relapse</title>
        <time_frame>5 years</time_frame>
        <population>Of the 43 recipients in the mismatched related donor cohort, 24 of those had leukemia. No recipients in the matched unrelated donor cohort had leukemia.</population>
        <group_list>
          <group group_id="O1">
            <title>T Cell Depletion Using CliniMACS®</title>
            <description>Recipients will receive T cell-depleted PBSC from eligible donors after receiving conditioning therapy using CliniMACS® device.
CliniMACS® (T cell depletion): Stem cells will be collected from donors after they receive Granulocyte colony-stimulating factor (G-CSF). The cells will be processed using the CliniMACS device to select for CD34+ stem cells and to deplete T cells. Recipients will receive conditioning therapy that is based on their disease type and then receive the CD34+ stem cells.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Post-transplant Leukemia Relapse</title>
          <population>Of the 43 recipients in the mismatched related donor cohort, 24 of those had leukemia. No recipients in the matched unrelated donor cohort had leukemia.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Transplant-related Mortality</title>
        <description>Transplant-related mortality includes death due to regimen-related toxicity or GVHD (all causes other than disease relapse). Those who died due to disease relapse are not included in the analyzed population for that time point.</description>
        <time_frame>2 year</time_frame>
        <population>Those who died due to disease relapse are not included in the analyzed population for that time point.</population>
        <group_list>
          <group group_id="O1">
            <title>T Cell Depletion Using CliniMACS®</title>
            <description>Recipients will receive T cell-depleted PBSC from eligible donors after receiving conditioning therapy using CliniMACS® device.
CliniMACS® (T cell depletion): Stem cells will be collected from donors after they receive Granulocyte colony-stimulating factor (G-CSF). The cells will be processed using the CliniMACS device to select for CD34+ stem cells and to deplete T cells. Recipients will receive conditioning therapy that is based on their disease type and then receive the CD34+ stem cells.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Transplant-related Mortality</title>
          <description>Transplant-related mortality includes death due to regimen-related toxicity or GVHD (all causes other than disease relapse). Those who died due to disease relapse are not included in the analyzed population for that time point.</description>
          <population>Those who died due to disease relapse are not included in the analyzed population for that time point.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 100</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="51"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 year</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="48"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 years</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="47"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Transplant-related Toxicities</title>
        <time_frame>1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>T Cell Depletion Using CliniMACS®</title>
            <description>Recipients will receive T cell-depleted PBSC from eligible donors after receiving conditioning therapy using CliniMACS® device.
CliniMACS® (T cell depletion): Stem cells will be collected from donors after they receive Granulocyte colony-stimulating factor (G-CSF). The cells will be processed using the CliniMACS device to select for CD34+ stem cells and to deplete T cells. Recipients will receive conditioning therapy that is based on their disease type and then receive the CD34+ stem cells.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Transplant-related Toxicities</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Thrombotic Microangiopathy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Idiopathic Pneumonia Syndrome</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Veno-occlusive Disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival</title>
        <time_frame>2 years</time_frame>
        <population>Subjects at least 2 years after transplant are evaluable for 2 year overall survival.</population>
        <group_list>
          <group group_id="O1">
            <title>Mismatched Related Donor Cohort: Malignant Disease</title>
            <description>Number of recipients alive following bone marrow transplant for malignant disease.</description>
          </group>
          <group group_id="O2">
            <title>Mismatched Related Donor: Non-malignant Disease</title>
            <description>Number of recipients alive following bone marrow transplant for non-malignant disease.</description>
          </group>
          <group group_id="O3">
            <title>Matched Unrelated Donor Cohort</title>
            <description>Number of recipients alive following bone marrow transplant for non-malignant disease.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival</title>
          <population>Subjects at least 2 years after transplant are evaluable for 2 year overall survival.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Device Performance: Dose of CD34+ Cells and CD3+ Cells Given</title>
        <description>For mismatched related donors, the target cell dose after processing is &gt;/= 20 x 10^6 CD34+ cells/kg patient body weight, but &gt;/= 8 x 10^6 is acceptable.
For unrelated donors the target cell dose after processing is &gt;/= 10 x 10^6 CD34+ cells/kg patient body weight, but &gt;/= 4 x 10^6 is acceptable.
The target T cell dose is &lt;/= 3 x 10^4 CD3+ cells/ kg.</description>
        <time_frame>Length of the trial (5 years)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Mismatched Related Donor Cohort</title>
          </group>
          <group group_id="O2">
            <title>Matched Unrelated Donor Cohort</title>
          </group>
        </group_list>
        <measure>
          <title>Device Performance: Dose of CD34+ Cells and CD3+ Cells Given</title>
          <description>For mismatched related donors, the target cell dose after processing is &gt;/= 20 x 10^6 CD34+ cells/kg patient body weight, but &gt;/= 8 x 10^6 is acceptable.
For unrelated donors the target cell dose after processing is &gt;/= 10 x 10^6 CD34+ cells/kg patient body weight, but &gt;/= 4 x 10^6 is acceptable.
The target T cell dose is &lt;/= 3 x 10^4 CD3+ cells/ kg.</description>
          <units>cells/ kg</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>x 10^6 CD34+ cells/ kg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.26" lower_limit="8.78" upper_limit="25.03"/>
                    <measurement group_id="O2" value="15.16" lower_limit="11.06" upper_limit="23.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>x 10^4 CD3+ cells/ kg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.02" lower_limit="0" upper_limit="1.1"/>
                    <measurement group_id="O2" value="0.3" lower_limit="0" upper_limit="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From the start of the conditioning regimen for transplant until 1 year after transplant</time_frame>
      <group_list>
        <group group_id="E1">
          <title>T Cell Depletion Using CliniMACS®</title>
          <description>Recipients will receive T cell-depleted PBSC from eligible donors after receiving conditioning therapy using CliniMACS® device.
CliniMACS® (T cell depletion): Stem cells will be collected from donors after they receive Granulocyte colony-stimulating factor (G-CSF). The cells will be processed using the CliniMACS device to select for CD34+ stem cells and to deplete T cells. Recipients will receive conditioning therapy that is based on their disease type and then receive the CD34+ stem cells.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="45" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Thrombotic microangiopathy</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Decreasing donor chimerism</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Leukopenia/ Neutropenia - grade 3</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Graft failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute gastroenteritis/ diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Pneumoatosis Intestinalis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Mucositis/ dehydration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Infusion reaction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Hypothermia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Graft vs. Host disease</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>HHV-6 Reactivation</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>CMV reactivation</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>EBV-related lymphoproliferative disease</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Infection w/ unknown absolute neutrophil count (ANC)</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Infection - grade 4</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Infection - eye</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration with hypernatremia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Relapse</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Seizures</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Hemorrhagic cystitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Renal &amp; Urinary disorder - grade 3</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Pulmonary/ Upper Respiratory- other</sub_title>
                <description>Blood tinged sputum, following fungal pneumonia</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Bronchopulmonary hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Aspiration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Thrombotic microangiopathy - grade 4</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Thrombotic microangiopathy - grade 3</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Elevated ALT - grade 4</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypokalemia - grade 4</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Seizures - grade 3</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Posterior Reversible Encephalopathy Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal and Urinary disorder - grade 3</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Renal disorder - grade 4</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoxia - grade 3</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Hypoxia - grade 4</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Idiopathic pneumonia syndrome</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash - grade 3</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension - grade 4</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Thrombosis - grade 3 (catheter-related)</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Andrew Gilman</name_or_title>
      <organization>PRA Health Sciences</organization>
      <phone>704-615-2744</phone>
      <email>gilmanandy@prahs.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

